Key result
DNA vaccines have minimal potential risks regarding genetic, immunologic, toxic, and environmental effects, though safety issues may differ case-by-case.
Why the study?
Are DNA vaccines safe in preclinical and clinical settings?
Are DNA vaccines safe in preclinical and clinical settings?
This review concludes that the potential risks of DNA vaccines are minimal based on current preclinical and clinical data.
Supports DNA vaccine advancement in trials; leaves open case-specific long-term monitoring in larger studies.
DNA vaccines are based on the transfer of genetic material, encoding an antigen, to the cells of the vaccine recipient. Despite high expectations of DNA vaccines as a result of promising preclinical data their clinical utility remains unproven. However, much data is gathered in preclinical and clinical studies about the safety of DNA vaccines. Here we review current knowledge about the safety of DNA vaccines. Safety concerns of DNA vaccines relate to genetic, immunologic, toxic, and environmental effects. In this review we provide an overview of findings related to the safety of DNA vaccines, obtained so far. We conclude that the potential risks of DNA vaccines are minimal. However, their safety issues may differ case-by-case, and they should be treated accordingly.
No takes yet. Share an insight, caveat, or question.
Schalk et al. (2006) conducted a review in Safety of DNA vaccines. DNA vaccines was evaluated on Safety (genetic, immunologic, toxic, and environmental effects). DNA vaccines have minimal potential risks regarding genetic, immunologic, toxic, and environmental effects, though safety issues may differ case-by-case.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: